Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis

“…In this issue of the Journal , Dooley and colleagues (pp. 929–935 ) report the 12-week results of the APT (Assessing Pretomanid for Tuberculosis) trial (NCT02256696), a phase II, open-label, randomized controlled trial in adults with smear-positive, drug-susceptible pulmonary TB conducted in Cape Town, South Africa ( 9 ). APT evaluated two experimental 12-week regimens composed of isoniazid, a rifamycin (rifampin or rifabutin), pretomanid, and pyrazinamide (given for 8 wk), compared with the initial 12 weeks of the standard of care control regimen, before all participants transitioned to continuation phase isoniazid and rifampin to complete a 6-month course.…”

The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China

“…The recently published clinical trials included shorter regimens such as Nix-TB regimens, Ze-Nix-TB regimens, and BPaLMfx, 11,34,35 which have a common characteristic of containing two novel drugs, Bdq and Pretomanid, which proved to be highly effective against MTB and had excellent evidence in clinical trials. [36][37][38] However, in areas with limited sources, a lack of novel drugs might result in making the traditional longer regimens or selecting at least four effective drugs in the regimens to ensure a favorable outcome. Prolonged use of Bdq is likely to occur when Bdq is only one kind of novel anti-TB drug in the regimens in the current clinics, especially in areas or countries with high TB burden.…”